Needham & Company
-
Needham & Company Raises Price Target to $70 on Cepheid (CPHD) Following 2Q15
-
Needham & Company Upgrades Cepheid (CPHD) to Buy
-
Needham & Company Starts Cepheid (CPHD) at Hold
-
Needham & Company Reiterates a 'Buy' on Cepheid (CPHD); Strong Systems Sales & Biothreat Revs, Guidance Increased
-
Needham & Company Reiterates a 'Buy' Rating on Cepheid (CPHD); 2Q10 EPS Beat on Higher Gross Margin & Lower R&D
-
Needham & Company Reiterates a 'Buy' on Cepheid (CPHD); Blood Culture Product Recall Unlikely to Impact MRSA Surveillance Business
-
Notable Analyst Rating Changes 04/23: YGE, WDC, CPHD, HSY Upgraded; VZ, DO, ASBC, NOK Downgraded
-
Needham & Company Reiterates a 'Buy' on Cepheid (CPHD); 1Q10 Beat on Strong Test Sales, 2010 Guidance Beatable
-
Unusual 11 Mid-Day Movers 10/14: CHIO, ACPW, JADE, CNO Higher; CXM, HILL, UCBH, UPI Lower
-
Needham & Co Upgrades Cepheid (CPHD) to Buy
-
Needham & Co Downgrades Cepheid (CPHD) to Hold

